Hope for diabetes immunotherapy

An immunotherapy treatment may be able to halt the progress of type 1 diabetes, British researchers have reported.

The treatment seeks to halt the autoimmune destruction of insulin-producing beta cells.

Early tests in London and Cardiff suggest that the treatment achieves "noticeable" changes in the behaviour of the immune system, it was announced last night.

The researchers at King’s College, London, and Cardiff University, have been using a treatment that uses peptides with the aim of "retraining" the immune system to stop attacking beta cells.

They reported their findings in Science Translational Medicine. Some 27 patients took part in the initial trial.

Researcher Professor Colin Dayan, from Cardiff, said: "It was encouraging to see that people who receive the treatment needed less insulin to control their blood glucose levels, suggesting that their pancreas was working better."

Fellow researcher Professor Mark Peakman, from King’s College, said: "We still have a long way to go, but these early results suggest we are heading in the right direction.

"The peptide technology used in our trial is not only appears to be safe for patients at this stage, but it also has a noticeable effect on the immune system."

Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes. Science Translational Medicine 9 August 2017 [abstract]

,

Leave a Reply

Your email address will not be published. Required fields are marked *

Search

Categories

Monthly Posts

Our Clients

BSH
Practice Index